Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 170Neoplasm Metastasis 13Prostatic Neoplasms, Castration-Resistant 11Metastatic Castration-resistant Prostate Cancer 7Neoplasms 6Metastatic Castration Resistant Prostate Cancer 6Breast Neoplasms 6Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 3Genital Neoplasms, Male 3Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Diseases, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Sleep Initiation and Maintenance Disorders 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1

Interventions

padeliporfin 4darolutamide 2apalutamide 2Abiraterone Acetate 2palladium-bacteriopheophorbide 1onapristone 1niraparib 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1enzalutamide 1abiraterone 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Imatinib Mesylate 1EPI-506 1Docetaxel 1BAY 86-7548 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Genital Diseases, Male × Abiraterone Acetate × Clear all
NCT01217697 2017-03-24

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved for marketing
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT02049190 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Arno Therapeutics

Phase 1/2 Unknown
75 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡